Related Experiment Video
Updated: May 25, 2026

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
Published on: September 11, 2019
[Kidney and HIV infection]
Emmanuelle Plaisier1, François-Xavier Lescure, Pierre Ronco
1Hôpital Tenon, service de néphrologie et dialyses, 75970 Paris, France. emmanuelle.plaisier@tnn.aphp.fr
Insights
Regular screening for chronic kidney disease (CKD) is crucial for all HIV-infected patients. Annual monitoring of glomerular filtration rate (GFR) and proteinuria is recommended, especially for high-risk individuals.
Area of Science:
- Nephrology
- Infectious Diseases
- Pharmacology
Background:
- Chronic kidney disease (CKD) is a significant concern in HIV-infected populations.
- Black patients exhibit a genetic predisposition to HIV-associated nephropathy.
- Antiretroviral therapy (ART) is vital for preventing and managing HIV-associated nephropathy.
Purpose of the Study:
- To emphasize the importance of screening and monitoring for CKD in HIV patients.
- To highlight the role of ART in preventing HIV-associated nephropathy.
- To guide the management of antiretroviral drug dosing based on kidney function.
Main Methods:
- Annual screening for CKD, including estimated glomerular filtration rate (eGFR) and proteinuria assessment.
- Kidney biopsy for definitive diagnosis of kidney diseases in HIV patients.
- Careful monitoring of eGFR and serum phosphorus, particularly with tenofovir therapy.
Main Results:
- Early detection and monitoring of CKD parameters are essential for HIV-infected individuals.
- ART effectively suppresses HIV replication, preventing or halting nephropathy progression.
- Renal toxicity associated with tenofovir requires vigilant assessment of eGFR and phosphorus levels.
Conclusions:
- Comprehensive CKD screening and annual monitoring are critical for all HIV patients.
- Kidney biopsy is the gold standard for diagnosing kidney diseases in this cohort.
- Adjusting antiretroviral dosing and monitoring for tenofovir-induced toxicity are crucial for patient safety.
Abstract:
Screening of chronic kidney disease (CKD) that includes estimation of the glomerular filtration rate (GFR) and evaluation proteinuria should be performed in all HIV-infected patients and these parameters have to be monitored annually in patients at higher risk for CKD. Black patients have a genetic predisposition to develop HIV-associated nephropathy. Suppression of HIV viral replication with antiretroviral therapy prevents the development of HIV-associated nephropathy or halts its progression. Kidney biopsy remains the most informative diagnosis test to differentiate various forms of kidney diseases in HIV-infected patients. Dosing antiretroviral agents with kidney metabolism should be adjusted when eGFR is bellow 50 mL/min/1.73 m(2). eGFR and serum phosphorus at baseline and during treatment should be carefully assessed in patients receiving tenofovir. Proximal renal tubular toxicity must be further evaluated in the presence of eGFR decrease and/or hypophosphatemia under tenofovir therapy.
Related Concept Videos
Kidney Transplant I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Sexually Transmitted Infections
Chronic Kidney Disease I: Introduction
Kidney Transplant III: Nursing Management
Kidney Transplant II: Surgical Procedure

